The broad objective of this proposal is to identify and characterize the most critical molecular sites of interaction between drugs with antipsychotic activity, or potential anti-attention deficit hyperactivity disorder (ADHD) activity, and their G protein-coupled receptor (GPCR) targets.
We aim to achieve an understanding of the molecular mechanisms of selective activation by agonists, and inactivation by inverse agonists, as well as the discriminant structural features of neutral antagonists that selectively bind to the D2 and D4 receptors and that are the targets for the drugs used to treat neuropsychiatric disorders. To achieve these objectives, molecular modeling techniques have been employed to predict receptor microdomains that might be interacting with selective and nonselective agonists and antagonists that were docked into rhodopsin-based models of dopamine D2 and D4 receptors. The inferences from these models will be probed with point mutations of the receptor microdomains that appear to be responsible for the functional interactions. In iterative studies, the binding and functional properties of the ligands will be determined in combinedcomputational and experimental protocols to test specific structure-based hypotheses in the mutant and wild type receptor constructs and to relate them to functional outcomes. The results will be interpreted as useful guides for the design of new putative therapeutic agents. The proposed studies will proceed as described in the following series of four interrelated specific aims: 1.) to utilize structural information about high affinity ligands in the structural context ofrhodopsin-based models for dopamine D2 and D4 GPCRs, in order to discriminate receptor microdomains and modes of ligand binding in relation to the agonist versus the antagonist activity of the ligands, 2.) to characterize the manner in which the structures of the ligands relate totheir ability to activate or inactivate dopamine D2 and D4 receptors based on different modes of binding and interaction within identified receptor microdomains, 3.) to determine if certain aromatic 1,4-disubstitutedpiperizine ligands that share an extraordinarily high selectivity for the D4 subtype of dopamine receptor are interacting with a common set of receptor microdomains, and 4.) to apply the combination of molecular models of ligand interaction in dopaminc receptor microdomains and modes of receptor activation, with experimental testing to probe new ligands predicted to have specified effects on D2 and D4 receptors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH063162-04
Application #
6855715
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Brady, Linda S
Project Start
2003-02-14
Project End
2008-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
4
Fiscal Year
2005
Total Cost
$317,362
Indirect Cost
Name
University of North Texas
Department
Pharmacology
Type
Other Domestic Higher Education
DUNS #
110091808
City
Fort Worth
State
TX
Country
United States
Zip Code
76107
Huang, Renqi; Chen, Zhenglan; Dolan, Sean et al. (2017) The dual modulatory effects of efavirenz on GABAA receptors are mediated via two distinct sites. Neuropharmacology 121:167-178
Dalwadi, Dhwanil A; Kim, Seongcheol; Amdani, Shahnawaz M et al. (2016) Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacol Res 110:10-24
Saunders, Christine; Siuta, Michael; Robertson, Sabrina D et al. (2014) Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function. Neurochem Int 73:113-121
Gatch, Michael B; Kozlenkov, Alexey; Huang, Ren-Qi et al. (2013) The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology 38:2373-84
Ericksen, Spencer S; Cummings, David F; Teer, Michael E et al. (2012) Ring substituents on substituted benzamide ligands indirectly mediate interactions with position 7.39 of transmembrane helix 7 of the D4 dopamine receptor. J Pharmacol Exp Ther 342:472-85
Cummings, David F; Canseco, Diana C; Sheth, Pratikkumar et al. (2010) Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem 18:4783-92
Cummings, David F; Ericksen, Spencer S; Goetz, Angela et al. (2010) Transmembrane segment five serines of the D4 dopamine receptor uniquely influence the interactions of dopamine, norepinephrine, and Ro10-4548. J Pharmacol Exp Ther 333:682-95
Lacivita, Enza; De Giorgio, Paola; Lee, Irene T et al. (2010) Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors. J Med Chem 53:7344-55
Chang, Chiung-Wen; Poteet, Ethan; Schetz, John A et al. (2009) Towards a quantitative representation of the cell signaling mechanisms of hallucinogens: measurement and mathematical modeling of 5-HT1A and 5-HT2A receptor-mediated ERK1/2 activation. Neuropharmacology 56 Suppl 1:213-25
Ericksen, Spencer S; Cummings, David F; Weinstein, Harel et al. (2009) Ligand selectivity of D2 dopamine receptors is modulated by changes in local dynamics produced by sodium binding. J Pharmacol Exp Ther 328:40-54

Showing the most recent 10 out of 18 publications